With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101012-12-8,2-Chloro-1,3-thiazole-5-carboxylic acid,as a common compound, the synthetic route is as follows.
2-Ch[oro-1,3-thiazo[e-4-carboxy[ic acid [CAS RN: 5198-87-8] (430 mg,2.55 mmo[, 1.0 eq) in 17 mL ethyl. acetate was treated with T3P solution [50 % in ethyl acetate] (3.80 mL, 6.37 mmol, 2.5 eq) and with acetohydrazide [CASRN: 1068-57-1] (189 mg, 2.55 mmol, 1.0 eq). The resulting solution was stirred at 80 C overnight. The reaction mixture was hydrolysed with ice-water and extracted with ethyl acetate (3x). The combined organic phases were washedwith brine. The phases were separated by the use of a Whatman filter. The volatile components of the resulting organic phase were removed in vacuo and the crude material contained 350 mg (50% yield of theory) of the title compound in 80% purity (UPLC area-%), which were used without further purification.UPLC-MS (Method 2): R = 0.90 mm; MS (EI0): m/z = 202 [M+H].1H-NMR (400 MHz, DMSO-d6): oe [ppm] = 2.41 (5, 3H), 8.71 (5, 1H).
101012-12-8, As the paragraph descriping shows that 101012-12-8 is playing an increasingly important role.
Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; BAeRFACKER, Lars; SIEMEISTER, Gerhard; HEINRICH, Tobias; PRECHTL, Stefan; STOeCKIGT, Detlef; ROTTMANN, Antje; WO2015/113927; (2015); A1;,
Thiazole | C3H3NS – PubChem
Thiazole | chemical compound | Britannica